Rethinking Treatment Goals in Psoriasis: Leveraging IL-17 Inhibitors to Move Beyond Skin Clearance Toward PsA Prevention - Episode 14
Evaluating Long-Term Remission and Disease Control with Bimekizumab in Psoriasis
In this episode, the panelists review long-term efficacy data for bimekizumab presented at EADV 2025, focusing on sustained remission and disease control in psoriasis. The experts highlight that approximately 49% of patients maintained complete skin clearance (PASI 100) from month 4 through year 4, with about 72% sustaining complete or near-complete clearance over the same period. They interpret these findings as strong evidence of durability and depth of response, underscoring bimekizumab’s ability to maintain remission over years rather than months. The discussion also includes nail outcomes, with nearly 80% of patients maintaining NAPSI 0, indicating resolution of nail involvement—an important factor given its association with psoriatic arthritis risk. The panelists emphasize that by achieving and maintaining high levels of clearance in both skin and nails, bimekizumab may help interrupt the inflammatory progression that leads to PsA, reinforcing its role in comprehensive disease control.
In this episode, the panelists review long-term efficacy data for bimekizumab presented at EADV 2025, focusing on sustained remission and disease control in psoriasis. The experts highlight that approximately 49% of patients maintained complete skin clearance (PASI 100) from month 4 through year 4, with about 72% sustaining complete or near-complete clearance over the same period. They interpret these findings as strong evidence of durability and depth of response, underscoring bimekizumab’s ability to maintain remission over years rather than months. The discussion also includes nail outcomes, with nearly 80% of patients maintaining NAPSI 0, indicating resolution of nail involvement—an important factor given its association with psoriatic arthritis risk. The panelists emphasize that by achieving and maintaining high levels of clearance in both skin and nails, bimekizumab may help interrupt the inflammatory progression that leads to PsA, reinforcing its role in comprehensive disease control.
